What are current recommendations for prevention and treatment of post-operative nausea and vomiting (PONV)?
txt 1
Introduction
Nausea and vomiting are a serious occurrence after surgery and anesthesia, which can negatively impact recovery and patient quality of life.1 Consensus guidelines on the management of postoperative nausea and vomiting (PONV) have been available for several years. The most recent edition, published in late 2025, proposes more widespread use of combination regimens for prophylaxis, as well as administering prophylaxis in patients who were previously thought to have a low risk for PONV. Table 1 summarizes currently known PONV risk factors.
table 1
| Table 1. Currently known PONV risk factors (adults).1 | |
|---|---|
| Increased PONV risk | Decreased PONV risk |
| Female gender History of PONV or motion sickness Nonsmoking status Use of postoperative opioids Surgery length >60 minutes Neutrophil/lymphocyte ratio >2 Bariatric surgery Laparoscopic cholecystectomy Urological surgery Knee arthroplasty Breast surgery Gynecologic surgery Obstetric surgery Microvascular decompression (neurosurgery) Intraoperative CSF loss Transgender individuals Pregnancy Anesthesia with nitrous oxide Age <50 years* Opioid use in the PACU* Ondansetron use in the PACU* | Preoperative physical fitness Higher Hgb and Hct BMI >25 kg/m2 Anesthesia with propofol TIVA Neuraxial and regional anesthesia Prophylactic analgesia with IV acetaminophen Analgesia with gabapentin/pregabalin Sugammadex Crystalloid administration |
| Abbreviations: BMI=body mass index; CSF=cerebrospinal fluid; Hct=hematocrit; Hgb=hemoglobin; IV=intravenous; PACU=postanesthesia care unit; PONV=postoperative nausea and vomiting; TIVA=total intravenous anesthesia. *Risk factor for post-discharge nausea and vomiting (PDNV). |
|
txt 2
Recommendations for PONV Prophylaxis in Adults
Table 2 summarizes current recommendations for prophylaxis of PONV in adults.1 The guidelines highlight a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist plus dexamethasone as the most well-studied combination (multiple randomized trials). Other effective combinations are a 5-HT3 receptor antagonist plus aprepitant (multiple randomized trials), aprepitant plus dexamethasone (multiple randomized trials), and ondansetron plus haloperidol (multiple randomized trials). The guideline authors did not identify sufficient data to recommend using lower doses as combination therapy than doses used for monotherapy. Although some studies have examined 3- and 4-drug combinations for PONV prophylaxis, the guideline does not currently recommend using more than 2 drugs.
table 2
| Table 2. Consensus recommendations for PONV prophylaxis in adults.1 | |
|---|---|
| Administer a 2-drug combination of any of the following: | |
| Drug class | Specific agents |
| 5-HT3 receptor antagonist | Ondansetron 4 mg IV or 16 mg orally at the end of surgery Palonosetron 0.075 mg IV (optimal timing not established) Granisetron 0.1 to 3 mg IV at the end of surgery |
| Glucocorticoid | Dexamethasone 4 to 8 mg IV at induction (8 mg may be the optimal dose) |
| Dopamine receptor antagonist | Amisulpride 5 mg IV (optimal timing not established) Droperidol 0.625 mg IV at the end of surgery Haloperidol 0.5 to 2 mg IV or IM (optimal timing not established) Olanzapine 10 mg PO |
| NK-1 receptor antagonist | Aprepitant 40 mg 80 mg PO or 32 mg IV at induction |
| Antihistamine | Dimenhydrinate 25 to 50 mg IV (optimal timing not established) Promethazine 6.25 mg (optimal timing not established) |
| Anticholinergic | Scopolamine transdermal starting the day before surgery or 2 hours before surgery |
| Other agents | Dexmedetomidine (optimal dose and timing not established) Ephedrine 0.5 mg/kg IM (optimal timing not established) |
| Abbreviations: 5-HT3=5-hydroxytryptamine-3; IM=intramuscular; IV=intravenous; NK=neurokinin; PO=by mouth; PONV=postoperative nausea and vomiting. | |
txt 3
Palonosetron is a first-line prophylactic medication that does not have a well-established optimal time of administration, possibly because its longer half-life (approximately 40 hours) allows more flexibility in the time of administration.1,2 The palonosetron package insert recommends administration immediately before induction of anesthesia.2 Various administration times for palonosetron have been documented in the literature, including before induction, after induction (immediately to as long as 20 minutes), before intubation, 20 to 30 minutes before the end of surgery, before extubation, postoperatively, and before discharge.3-9
Individuals who are at risk of post-discharge nausea and vomiting (PDNV) should receive prophylactic antiemetics before discharge.1 The preferred long-acting options currently include palonosetron, olanzapine (immediate release or orally disintegrating tablet), or ramosetron (orally disintegrating tablet).
Recommendations for PONV Prophylaxis in Children
Risk factors for PONV in children are different than adults and validated pediatric models for predicting PONV should be used in this population.1 The most well-established strategy for minimizing PONV risk is anesthesia with propofol total intravenous anesthesia (TIVA) rather than inhaled agents.
In general, a single medication for prophylaxis is recommended for children without PONV risk factors, and 2-drug combination therapy is recommended for children with risk factors.1 Pharmacologic PONV prophylactic agents with the most evidence in children are the 5-HT3 receptor antagonists (mainly ondansetron 0.1 mg/kg up to 4 mg) and dexamethasone (0.15 mg/kg up to 4 mg). Combination therapy with ondansetron plus dexamethasone is supported by multiple randomized trials.
Recommendations for PONV Treatment
Patients who experience PONV, whether prophylaxis was used or not, should receive antiemetic treatment.1 For both adults and children, if prophylaxis was used, the drug used for treatment should be from a different drug class. In adults, a second dose of a short-acting 5-HT3 receptor antagonist should be used if more than 6 hours has elapsed since the first dose. Long-acting antiemetics (eg, aprepitant, fosaprepitant, palonosetron) should not be re-dosed during post-anesthesia care.
Conclusion
Proactive management of PONV includes management of risk factors, prophylactic therapy (both during recovery and after discharge), and prompt treatment when needed. Evidence supporting combination prophylactic therapy is growing, and the most recent consensus guidelines recommend combination prophylaxis in adults and in children with risk factors for PONV. Treatment of PONV consists of rescue therapy with an antiemetic from a different class than was used for prophylaxis, although administering a second dose of 5-HT3 receptor antagonists can also be considered depending on timing.
References
- Gan TJ, Jin Z, Ayad S, et al. Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting: Executive Summary. Anesth Analg. Published online November 14, 2025. doi:10.1213/ANE.0000000000007816
- Palonosetron injection [package insert]. Baxter Healthcare Corporation; September 2020.
- Kumar J, Alagarsamy R, Lal B, et al. Comparison of efficacy and safety between palonosetron and ondansetron to prevent postoperative nausea and vomiting in patients undergoing laparoscopic surgery: a systematic review and meta-analysis. J Minim Invasive Surg. 2024;27(4):202-216. doi:10.7602/jmis.2024.27.4.202
- Yu TT, Han LH, Zhao JH, Fu JJ, Fang PP, Lu Y. Effects of motion sickness patch on postoperative nausea and vomiting in female patients undergoing thyroid surgery: a randomized clinical trial. Int J Surg. 2025;111(10):7001-7009. doi:10.1097/JS9.0000000000002875
- Song JW, Shim JK, Choi SH, Soh S, Jang J, Kwak YL. Comparison of ramosetron and palonosetron for preventing nausea and vomiting after spinal surgery: association with ABCB1 polymorphisms. J Neurosurg Anesthesiol. 2017;29(4):406-414. doi:10.1097/ANA.0000000000000361
- Cho E, Kim DH, Shin S, Kim SH, Oh YJ, Choi YS. Efficacy of palonosetron-dexamethasone combination versus palonosetron alone for preventing nausea and vomiting related to opioid-based analgesia: a prospective, randomized, double-blind trial. Int J Med Sci. 2018;15(10):961-968. Published 2018 Jun 13. doi:10.7150/ijms.24230
- Yoo JH, Kim SI, Chung JW, Jun MR, Han YM, Kim YJ. Aprepitant in combination with palonosetron for the prevention of postoperative nausea and vomiting in female patients using intravenous patient-controlled analgesia. Korean J Anesthesiol. 2018;71(6):440-446. doi:10.4097/kja.d.18.00011
- Lim JA, Jo S, Choi EK. Comparison of the antiemetic efficacy of a combination of midazolam with ramosetron and midazolam with palonosetron for postoperative nausea and vomiting prophylaxis in laparoscopic cholecystectomy. Medicine (Baltimore). 2023;102(52):e36824. doi:10.1097/MD.0000000000036824
- Bhargava T, Sahu S, Singh TK, et al. Comparison of palonosetron and ondansetron in preventing postoperative nausea and vomiting in renal transplantation recipients: a randomized clinical trial. Braz J Anesthesiol. 2024;74(1):744251. doi:10.1016/j.bjane.2021.07.027
Prepared by:
Heather Ipema, PharmD, BCPS
Clinical Assistant Professor, Drug Information Specialist
University of Illinois Chicago Retzky College of Pharmacy
May 2026
The information presented is current as of April 24, 2026. This information is intended as an educational piece and should not be used as the sole source for clinical decision-making.